With a goal to develop novel therapies to prevent deaths and improve lives, this firm is at the forefront of the global fight against infections.
Appili Therapeutics (TSX:APLI) is an infectious disease biopharmaceutical company with a mission to solve life-threatening infections. The firm is part of a consortium sponsoring late-stage clinical trials evaluating the antiviral Avigan/Reeqonus for the worldwide treatment and prevention of COVID-19.
Funding proceeds will help with the firm’s Phase 3 PRESECO trial, which is evaluating an oral antiviral for the treatment of mild-to-moderate COVID-19, to deliver this critically needed medicine and hopefully change the trajectory of this pandemic.
Shares were trading up near 3% in afternoon trade.
